THE USE OF ENOXAPARIN AND RIVAROXABAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Main Article Content

Аннотация:

Chronic kidney disease (CKD) is a progressive condition that affects the structure and function of the kidneys over time. Patients with CKD are at an increased risk for thromboembolic events due to abnormalities in coagulation and fibrinolysis. Anticoagulants such as enoxaparin (a low molecular weight heparin) and rivaroxaban (a direct oral anticoagulant) are commonly used to prevent and treat thromboembolism. However, the use of these agents in CKD patients is complicated by altered pharmacokinetics and pharmacodynamics due to impaired renal clearance. This thesis aims to compare the safety and efficacy of enoxaparin and rivaroxaban in patients with CKD, considering their renal-specific limitations, adverse effects, and therapeutic outcomes.

Article Details

Как цитировать:

Salimov , J., Umarova , Z., & Nazarova , N. (2025). THE USE OF ENOXAPARIN AND RIVAROXABAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Инновационные исследования в современном мире: теория и практика, 4(3), 105–106. извлечено от https://in-academy.uz/index.php/zdit/article/view/43904

Библиографические ссылки:

Filippatos, G., & Elisaf, M. (2022). "Anticoagulation in Chronic Kidney Disease: Focus on Safety and Efficacy." Nephrology Dialysis Transplantation.

Limdi, N. A., & Beasley, T. M. (2018). "Anticoagulation in Patients with CKD." American Journal of Kidney Diseases.

Connolly, S. J., et al. (2020). "Rivaroxaban versus Warfarin in CKD Patients with Atrial Fibrillation." New England Journal of Medicine.

Malhotra, R., & Kashani, K. (2019). "Pharmacokinetics of Anticoagulants in CKD." Clinical Journal of the American Society of Nephrology.

Chan, K. E., et al. (2018). "Safety of Anticoagulants in CKD." Journal of the American Society of Nephrology.

KDIGO. (2021). "Clinical Practice Guideline for Glomerular Diseases." Kidney International Supplements.

Turpie, A. G. G. (2018). "Low Molecular Weight Heparin in CKD Patients." Thrombosis and Haemostasis.

Weitz, J. I., et al. (2019). "Direct Oral Anticoagulants in CKD." Blood Journal.